Stay updated on Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page
- Check3 days agoChange DetectedAccess to the study record now displays a 403 Forbidden error page instead of the study content. The page header shows 403 Forbidden and includes a Home link, indicating an access restriction rather than the study details being shown.SummaryDifference18%

- Check10 days agoChange DetectedThe page's revision tag was updated to v3.7.0, replacing the previous v3.6.6 in the site's revision history.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page’s revision tag was updated from v3.6.5 to v3.6.6, indicating a site update. This update does not alter the study details or public content displayed on the page.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page’s revision label was updated from v3.6.4 to v3.6.5, indicating a backend/template update. No study content or user-facing information is altered.SummaryDifference0.0%

- Check52 days agoChange DetectedThe study's list of participating centers was updated. Cooperman Barnabas Medical Center and UPMC Hillman Cancer Center were added as sites, while Saint Barnabas Medical Center and the University of Pittsburgh Cancer Institute (UPCI) were removed.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now shows revision v3.6.4, replacing the previous revision v3.6.3, indicating an updated page version.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Chemotherapy in Endometrial Cancer Clinical Trial page.